抗骨质疏松药物不同给药途径研究进展

Development of the drug delivery approaches for osteoporosisd

随着老龄化社会的来临,骨质疏松症已经成为了世界范围内的主要健康问题之一。目前,临床上抗骨质疏松药物诸如双膦酸盐类、激素类、以及较新的骨细胞活性调节剂等,主要通过口服、静脉或皮下给药,这些传统方法都存在患者依从性差或生物利用度低的缺陷。为了更高效的治疗骨质疏松症及防范相关骨折风险,研究者们近年来在抗骨质疏松症的给药途径领域取得许多突破,利用纳米载体、骨靶向性基团修饰药物、被动和主动触发的储库系统都可以通过控制药物释放的速率、时间和作用部位提高治疗剂疗效、安全性及患者依从性。本文就抗骨质疏松症治疗的给药途径及新兴给药方法进行综述。

Osteoporosis have become the major public health problems worldwide in our aging society.Currently,Most of the clinically used antiresorptive and anabolic agents such bisphosphonates,asestrogen,along with newer modulators and antibodies,are primarily administered orally,intravenously,or subcutaneously.Traditional methods have defects of poor patient compliance or low bioavailability.In recent years,breakthroughs in the field of drug delivery have been made to treat osteoporosis and associated fracture risk more efficiently.The use of nano carriers,bone targeted group modified drugs,passively and active actively triggered release system can improve the efficacy and safety of therapeutic agents by controlling the rate,time andplace of drug release.This paper reviews routes of administration for treatment of osteoporosis with emphasis on emerging drug delivery routes.